Chemotherapy for breast cancer (review)

Oncology Reports

Volumn 24, Issue 5, 2010, Pages 1121-1131

  Hassan, M Sultan U ^a   Ansari, J ^b   Spooner, D ^c   Hussain, S A ^c  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Anthracyclines; Breast cancer; Chemotherapy; Metastatic breast cancer; Taxanes

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; MELPHALAN; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PREDNISOLONE; TAMOXIFEN; TRASTUZUMAB; VINBLASTINE;

BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SCREENING; CARDIOTOXICITY; DISEASE FREE SURVIVAL; DRUG POTENTIATION; DRUG SUBSTITUTION; FEVER; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; MASTECTOMY; METASTASIS BREAST CANCER; METASTATIC BREAST CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS;

EID: 78149289508     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000963     Document Type: Review

References (67)

1. Guarneri V and Conte PF: The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 31 (Suppl. 1): S149-S161, 2004.
2. (EBCTCG). EBCTCG: Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 355: 1757-1770, 2000.
3. Hussain SA, Palmer DH, Stevens A, Spooner D, Poole CJ and Rea DW: Role of chemotherapy in breast cancer. Expert Rev Anticancer Ther 5: 1095-1110, 2005.
4. Peto R, Boreham J, Clarke M, Davies C and Beral V: UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355: 1822, 2000.
5. (EBCTCG). EBCTCG: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
6. Henson ES, Hu X and Gibson SB: Herceptin sensitizes erbB2- overexpressing cells to apoptosis by reducing antiapoptotic MCL-1 expression. Clin Cancer Res 12: 845-853, 2006.
7. Pusztai L, Symmans FW and Hortobagyi GN: Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 12: 73-85, 2005.
8. Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE and Noer RJ: Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 168: 337-356, 1968.
9. Fisher B, Carbone P, Economou SG, et al: 1-phenylalanine mustard (l-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 292: 117-122, 1975.
10. Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405-410, 1976.
11. Fumoleau P, Kerbrat P, Romestaing P, et al: Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 21: 298-305, 2003.
12. Panel. NIoHCD: Conference statement: adjuvant therapy for breast cancer. J Natl Cancer Inst 93: 979-989, 2000.
13. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357-3365, 2003. (Pubitemid 46606270)
14. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8: 1483-1496, 1990.
15. Coombes RC, Bliss JM, Wils J, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 14: 35-45, 1996.
16. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National cancer institute of Canada clinical trials group. J Clin Oncol 16: 2651-2658, 1998.
17. Pritchard KI, Levine MN, Bramwell VHC, et al: A randomized trial comparing cef to CMF in premenopausal women with node positive breast cancer: update of NCIC CTG MA. 5. Breast Cancer Res Treat 76: S33, 2002.
18. Group FES: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6: 679-688, 1988.
19. Epirubicin IMBSw: Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol 6: 976-982, 1988.
20. Poole CJ, Earl HM, Hiller L, et al: Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. Neat investigators and the SCTBG. N Engl J Med 355: 1851-1862, 2006.
21. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976-983, 2003.
22. Group FAS: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of french adjuvant study group 05 randomized trial. J Clin Oncol 19: 602-611, 2001.
23. Bonneterre J, Roche H, Kerbrat P, et al: Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23: 2686-2693, 2005.
24. Crown J, O'Leary M and Ooi WS: Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9 (Suppl. 2): 24-32, 2004.
25. Buzdar AU, Singletary SE, Valero V, et al: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 8: 1073-1079, 2002.
26. Nowak AK, Wilcken NR, Stockler MR, Hamilton A and Ghersi D: Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 5: 372-380, 2004.
27. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005.
28. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672, 2005.
29. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2354, 1999.
30. Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a european organization for research and treatment of cancer randomized study with cross-over. J Clin Oncol 18: 724-733, 2000.
31. Fossati R, Confalonieri C, Torri V, et al: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439-3460, 1998.
32. Cocconi G: Chemotherapy with and without anthracycline. J Clin Oncol 18: 1392-1393, 2000.
33. Gabizon A, Catane R, Uziely B, et al: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992, 1994.
34. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
35. Reichman BS, Seidman AD, Crown JP, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943-1951, 1993.
36. Nabholtz JM, Senn HJ, Bezwoda WR, et al: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 study group. J Clin Oncol 17: 1413-1424, 1999.
37. Bonneterre J, Spielman M, Guastalla JP, et al: Efficacy and safety of docetaxel (taxotere) in heavily pretreated advanced breast cancer patients: the french compassionate use programme experience. Eur J Cancer 35: 1431-1439, 1999.
38. Bishop JF, Dewar J, Toner GC, et al: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 17: 2355-2364, 1999.
39. Icli E, Akbulut H, Uner A, et al: Paclitaxel (t) vs cisplatin + VP- 16 (EP) in metastatic breast cancer patients treated with anthracyclines: a phase III randomized study. Turkish Oncology Group. Ann Oncol 13: 47, 2002.
40. Sledge GW, Neuberg D, Bernardo P, et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588-592, 2003.
41. Ravdin P, Erban J, Overmoyer B, et al: Phase III comparison of docetaxel and paclitaxel in patients with metastatic breast cancer. Eur J Cancer 1: S201, 2003.
42. Tabernero J, Climent MA, Lluch A, et al: A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15: 1358-1365, 2004.
43. Winer EP, Berry DA, Woolf S, et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22: 2061-2068, 2004.
44. Biganzoli L, Cufer T, Bruning P, et al: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 20: 3114-3121, 2002.
45. Jassem J, Pienkowski T, Pluzanska A, et al: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19: 1707-1715, 2001.
46. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995.
47. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5- fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281, 1998.
48. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493, 1999.
49. Jones S, Winer E, Vogel C, et al: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13: 2567-2574, 1995.
50. Carmichael J, Possinger K, Phillip P, et al: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13: 2731-2736, 1995.
51. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J and Melemed A: Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62: 2-8, 2002.
52. Smorenburg CH, Bontenbal M, Seynaeve C, et al: Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66: 83-87, 2001.
53. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
54. Pegram MD and Slamon DJ: Combination therapy with trastuzumab (herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 26: 89-95, 1999.
55. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019, 1998.
56. Kurosumi M, Tabei T, Suemasu K, et al: Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 7: 945-948, 2000.
57. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline- pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823, 2002.
58. Andre F, Broglio K, Roche H, et al: Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol 26: 2636-2643, 2008.
59. Hayes DF, Thor AD, Dressler LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357: 1496-1506, 2007.
60. Jones S, Holmes FA, O'Shaughnessy J, et al: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27: 1177-1183, 2009.
61. Kostopoulos I, Arapantoni-Dadioti P, Gogas H, et al: Evaluation of the prognostic value of hER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Breast Cancer Res Treat 96: 251-261, 2006.
62. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312, 2007.
63. Pusztai L: Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol 18 (Suppl. 12): xii15-20, 2007.
64. Mechetner E, Kyshtoobayeva A, Zonis S, et al: Levels of multi-drug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4: 389-398, 1998.
65. Trock BJ, Leonessa F and Clarke R: Multidrug resistance in breast cancer: a meta-analysis of MDR1/GP170 expression and its possible functional significance. J Natl Cancer Inst 89: 917-931, 1997.
66. Carlson RW, O'Neill AM, Goldstein LJ, et al: A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Invest 24: 677-681, 2006.
67. Bedard PL, Di Leo A and Piccart-Gebhart MJ: Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 7: 22-36, 2010.